Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Eric J. Buller"'
Autor:
Glen Mills, Brian C. Barnes, M. Felicia Fontenot, Joseph E. Brierre, James L. Cole, Siva Yadlapati, David A. Rinaldi, Nancy A. Lormand, Eric J. Buller, John M. Rainey
Publikováno v:
Cancer. 95:1274-1278
BACKGROUND Multiple trials have been performed to evaluate second-line clinical chemotherapy in patients with advanced nonsmall cell lung carcinoma (NSCLC). However, no single agent or combination has demonstrated superior activity. METHODS Patients
Autor:
David A. Rinaldi, John M. Rainey, Eric J. Buller, Joseph E. Brierre, M. Patrick Stagg, James L. Cole, Nancy A. Lormand, M. Felicia Fontenot
Publikováno v:
American journal of clinical oncology. 25(5)
The major purposes of this study were to determine the maximally tolerated dose (MTD), dose-limiting toxicity (DLT), toxicity profile, and antitumor activity of gemcitabine and paclitaxel combination therapy when administered to patients with advance
Autor:
Fontenot Mf, James L. Cole, Nancy A. Lormand, David A. Rinaldi, John M. Rainey, Joseph E. Brierre, Eric J. Buller, Stagg Mp
Publikováno v:
American journal of clinical oncology. 23(1)
The major purposes of this study were to determine the maximally tolerated dose (MTD), dose-limiting toxicity (DLT), toxicity profile, and antitumor activity of gemcitabine (GEM) (Gemzar) and 5-fluorouracil (5-FU) combination therapy when administere